The company is expanding to bring its technology to the clinical antimicrobial susceptibility testing (AST) markets.
The company is currently commercially leveraging the Horizon 2020 funded Phase II (AST) project – in which multi-resistant bacterial infections will be clinically validated using Symcel’s screening method.
“Our business development strategy has evolved and is now twofold: we will be targeting growth both from sales to the big clinical microbiology market, as well as increasing revenues from key research markets including metabolic, microbiology and 3D culturing applications. Currently, we will focus sales activities specifically on the microbiology research market – especially targeting developers of antibiotics in academia and industry as well as scientists working on solutions to biofilm formation and antimicrobial resistance,” commented Jesper Ericsson, CEO of Symcel.
Pushing clinical market growth
Symcel has brought on board a number of business drivers to push clinical market growth.
Dr. Marta Veses Garcia, Symcel’s new application scientist, will lead the experimental work within the Horizon 2020 project together with scientific partners from the Karolinska Institutet and other European research institutes. She is a scientific expert in antimicrobial sensitivity testing methods who previously worked for the Karolinska Institutet in Stockholm, Sweden. At Karolinska, she developed a novel diagnostic chip for antibiotic resistance and has expert knowledge of the requirements for developing experimental designs in-line with clinical and regulatory requirements.
Dr Karin Gillner joins Symcel as a project manager tasked with running the Horizon 2020 project including from an innovation management perspective. She has over 15 years experience of research, project management and coordination of multicenter studies.
Pelle Friberg joins Symcel as its sales lead and will work closely with the CEO on the company’s sales and marketing strategy. Prior to this, he worked for BioLamina where he was instrumental in building up key accounts and direct sales strategies within the cell-based assays research market in Europe.